Document Detail

Switching to Raltegravir in Virologically Suppressed in HIV-1-Infected Patients: A Retrospective, Multicenter, Descriptive Study.
MedLine Citation:
PMID:  23061598     Owner:  NLM     Status:  Publisher    
Objectives: To describe the efficacy and tolerability of switching to raltegravir (RAL) in virologically suppressed HIV-1-infected patients during routine clinical practice. Methods: A total of 263 subjects (189 men, median age 48.1 years) with HIV-1 RNA < 50 copies/mL for ≥ 6 months were switched to RAL (400 mg b.i.d). Reasons for change were toxicity (49.0%), drug interactions (6.1%) or convenience (28.6%) (switch from subcutaneous to oral treatment 22.4%, improvement of posology 3.4%). Patients were followed up to 24 months after switching to RAL. Primary end-points were tolerability and virological failure defined as two consecutive measures of HIV-1 RNA > 50 copies/mL. Results: After a median of 12.4 months (range 2.8-26.4 months), virological failure was observed in 6 (2.3%) patients (2.2 per 100 person-years,[95%CI 0.9-4.6]), while AIDS occurred in 1, drug discontinuation in 4, 3 patients died and 10 were lost to follow-up. The median CD4+ T cell count increased from 460 cells/mm3 to 508.6 cells/mm3 (P < 0.001). Conclusions: Switching to RAL in clinical practice was mainly driven by toxicity, convenience or interactions, they were well tolerated and secured virologic suppression in the vast majority of patients.
Daniel Podzamczer; Esteban Martínez; Pere Domingo; Elena Ferrer; Pompeyo Viciana; Jordi Curto; Maria-Jesús Pérez-Elías; Antonio Ocampo; Ignacio Santos; Hernando Knobel; Vicente Estrada; Eugenia Negredo; Ferrán Segura; Joaquín Portilla; Esteban Ribera; Josefa Galindo; Antonio Antela; Jorge Carmena; Manuel Castaño
Related Documents :
11824878 - The development of a protocol for the use of 5-ht3 antagonists in chemotherapy-induced ...
24499078 - Randomized pilot trial between prostaglandin i2 analog and anti-platelet drugs on perip...
16507198 - Total intravenous anaesthesia with propofol and remifentanil for elective neurosurgical...
23084428 - Melatonin and cortisol rhythm in patients with extensive nasal polyposis.
8881948 - The role of an advanced thermotherapy device in prostatic voiding dysfunction.
20425118 - Tracheal defect repair using a plga-collagen hybrid scaffold reinforced by a copolymer ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-04
Journal Detail:
Title:  Current HIV research     Volume:  -     ISSN:  1873-4251     ISO Abbreviation:  Curr. HIV Res.     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-15     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101156990     Medline TA:  Curr HIV Res     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
HIV Unit, Infectious Disease Service, Hospital Universitari de Belvitge, C/Feixa Llarga s/n, E-08907 L'Hospitalet de Llobregat, Barcelona, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Colectomy with ileorectal anastomosis has a worse 30-day outcome when performed for colonic inertia ...
Next Document:  The Effect of Unsuccessful Treatment with Peginterferon and Ribavirin on the Liver Fibrosis Course o...